Arvinas logo

Arvinas Share Price (NASDAQ: ARVN)

$7.39

0.07

(0.96%)

Live

Last updated on

Check the interactive Arvinas Stock chart to analyse performance

Arvinas stock performance

as on August 26, 2025 at 12:41 AM IST

  • Today's Low:$7.30
    Today's High:$7.40

    Day's Volatility :1.35%

  • 52 Weeks Low:$5.90
    52 Weeks High:$29.61

    52 Weeks Volatility :80.07%

Arvinas Stock Returns

PeriodArvinas IncSector (Health Care)Index (Russel 2000)
3 Months
9.42%
6.0%
0.0%
6 Months
-56.3%
-7.2%
0.0%
1 Year
-72.7%
-11.1%
0.0%
3 Years
-83.45%
5.5%
-10.0%

Arvinas Inc Key Stats

Check Arvinas key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$7.32
Open
$7.28
Today's High
$7.53
Today's Low
$7.3
Market Capitalization
$537.4M
Today's Volume
$1.4M
52 Week High
$29.6106
52 Week Low
$5.9
Revenue TTM
$372.8M
EBITDA
$-113.8M
Earnings Per Share (EPS)
$-1.01
Profit Margin
-19.47%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-12.01%

Stock Returns calculator for Arvinas Stock including INR - Dollar returns

The Arvinas stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Arvinas investment value today

Current value as on today

₹31,899

Returns

₹68,101

(-68.1%)

Returns from Arvinas Stock

₹72,436 (-72.44%)

Dollar Returns*

₹4,335 (+4.33%)

Indian investors sentiment towards Arvinas Stock

16%

Period: Jul 25, 2025 to Aug 24, 2025. Change in 30 Days versus previous period

Search interest for Arvinas Stock from India on INDmoney has increased by 16% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Arvinas Inc

  • Name

    Holdings %

  • Vanguard Group Inc

    12.83%

  • BlackRock Inc

    8.43%

  • Citadel Advisors Llc

    5.29%

  • Pfizer Inc

    4.72%

  • D. E. Shaw & Co LP

    2.94%

  • State Street Corp

    2.59%

Analyst Recommendation on Arvinas Stock

Rating
Trend

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 26 Wall street analysts offering stock ratings for Arvinas(by analysts ranked 0 to 5 stars)

Arvinas Share Price Target

What analysts predicted

Upside of 149.59%

Target:

$18.44

Current:

$7.39

Arvinas share price target is $18.44, a slight Upside of 149.59% compared to current price of $7.39 as per analysts' prediction.

Arvinas Stock Insights

  • Price Movement

    In the last 6 months, ARVN stock has moved down by -58.6%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 188.8M → 22.4M (in $), with an average decrease of 88.1% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 82.9M → -61.2M (in $), with an average decrease of 173.8% per quarter
  • ARVN vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.7% return, outperforming this stock by 138.7%
  • ARVN vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.4% return, outperforming this stock by 196.7%
  • Price to Sales

    ForARVN every $1 of sales, investors are willing to pay $1.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Arvinas Inc Financials

Revenue
Profit
Cash Flow
Annually
Quarterly
FY19
FY20
FY21
FY22
FY23
FY24
FY24Y/Y Change
Revenue
$263.4M
↑ 235.54%
Net Income
$-198.9M
↓ 45.85%
Net Profit Margin
-75.51%
↑ 392.39%

Arvinas Technicals Summary

Sell

Neutral

Buy

Arvinas is currently in a neutral trading position according to technical analysis indicators.

Arvinas Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Arvinas Inc logo
-3.81%
-56.3%
-72.7%
-83.45%
-70.85%
Regeneron Pharmaceuticals, Inc. logo
5.52%
-17.35%
-50.85%
-1.12%
-3.68%
Beone Medicines Ltd logo
6.51%
21.35%
57.45%
73.21%
25.84%
Vertex Pharmaceuticals Incorporated logo
-14.26%
-17.97%
-18.13%
40.27%
45.64%
Alnylam Pharmaceuticals, Inc. logo
39.9%
82.53%
68.83%
115.41%
241.51%

About Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Organization
Arvinas
Employees
430
CEO
Dr. John G. Houston Ph.D.
Industry
Health Technology

Key Management of Arvinas Inc

NameTitle
Dr. John G. Houston Ph.D.
Chairperson, CEO & President
Mr. Andrew R. Saik
CFO & Treasurer
Ms. Angela M. Cacace Ph.D.
Chief Scientific Officer
Dr. Randy Teel Ph.D.
Chief Business Officer
Dr. Noah Berkowitz M.D., Ph.D.
Chief Medical Officer
Mr. David K. Loomis M.B.A.
VP & Chief Accounting Officer
Mr. Jeff Boyle
Vice President of Investor Relations
Mr. Jared M. Freedberg J.D.
General Counsel & Corporate Secretary
Mr. Steve Weiss
Senior VP & Chief Human Resources Officer
Ms. Lisa Sinclair
Senior Vice President of Corporate Operations

Important FAQs about investing in ARVN Stock from India :

What is Arvinas share price today?

Arvinas share price today is $7.39 as on . Arvinas share today touched a day high of $7.40 and a low of $7.30.

What is the 52 week high and 52 week low for Arvinas share?

Arvinas share touched a 52 week high of $29.61 and a 52 week low of $5.90. Arvinas stock price today i.e. is trending at $7.39, lower by 75.04% versus the 52 week high.

How to invest in Arvinas Stock (ARVN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Arvinas on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Arvinas Shares that will get you 0.2030 shares as per Arvinas share price of $7.39 per share as on August 26, 2025 at 12:41 AM IST.

What is the minimum amount required to buy Arvinas Stock (ARVN) from India?

Indian investors can start investing in Arvinas (ARVN) shares with as little as ₹87.537 or $1 (as of August 25, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.37 in Arvinas stock (as per the Rupee-Dollar exchange rate as on August 25, 2025). Based on Arvinas share’s latest price of $7.39 as on August 26, 2025 at 12:41 AM IST, you will get 1.3532 shares of Arvinas. Learn more about fractional shares .

What are the returns that Arvinas has given to Indian investors in the last 5 years?

Arvinas stock has given -70.85% share price returns and 18.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?